Roles of Pim-3, a novel survival kinase, in tumorigenesis

Cancer Science

Volumn 102, Issue 8, 2011, Pages 1437-1442

  Mukaida, Naofumi ^a   Wang, Ying Ying ^a   Li, Ying Yi ^a,b  

^a KANAZAWA UNIVERSITY   (Japan)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 3; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE PROGRESSION; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS;

EID: 79960411328     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01966.x     Document Type: Review

References (60)

1. Feldman JD, Vician L, Crispino M et al. KID-1, a protein kinase induced by depolarization in brain. J Biol Chem 1998; 273: 16535-43.
2. Konietzko U, Kauselmann G, Scafidi J et al. Pim kinase expression is induced by LTP stimulation and required for the consolidation of enduring LTP. EMBO J 1999; 18: 3359-69.
3. Cuypers HT, Selten G, Quint W et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 1984; 37: 141-50.
4. Verbeek S, van Lohuizen M, van der Valk M et al. Mice bearing the E-μ-myc and E-μ-pim-1 transgenes develop pre-B-cell leukemia prenatally. Mol Cell Biol 1991; 11: 1176-9.
5. Breuer ML, Cuypers HT, Berns A. Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas. EMBO J 1989; 8: 743-8.
6. Wendel HG, De Stanchina E, Fridman JS et al. Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-7.
7. van Lohuizen M, Verbeek S, Krimpenfort P et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell 1989; 56: 673-82.
8. Hammerman PS, Fox CJ, Birnbaum M et al. Pim and Akt oncogenes are independent regulators of hematopoieitic cell growth and survival. Blood 2005; 105: 4477-83.
9. Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 2005; 115: 2618-24.
10. Lindsley CW. The Akt/PKN family of protein kinases: a review of small molecule inhibitors and progress towards target validation: a 2009 update. Curr Top Med Chem 2010; 10: 458-77.
11. Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer 2011; 11: 23-34.
12. Zhu N, Ramirez LM, Lee RL et al. CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-κB pathway. J Immunol 2002; 168: 744-54.
13. Fox CJ, Hammerman PS, Cinalli RM et al. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev 2003; 17: 1841-54.
14. Fujii C, Nakamoto Y, Lu P et al. Aberrant expression of serine/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines. Int J Cancer 2005; 114: 209-18.
15. Qian KC, Wang L, Hickey ER et al. Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 2005; 280: 6130-7.
16. Bullock AN, Debreczeni J, Amos AL et al. Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 2005; 280: 41675-82.
17. Bullock AN, Russo S, Amos A et al. Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor. PLoS ONE 2009; 4: e7112.
18. Zhang P, Wang H, Min X et al. Pim-3 is expressed in endothelial cells and promotes vascular tube formation. J Cell Physiol 2009; 220: 82-90.
19. Lu A, Tang Y, Ran R et al. Genomics of the periinfarction cortex after focal cerebral ischemia. J Cereb Blood Flow Metab 2003; 23: 786-810.
20. Liu A, He M, Yi B et al. Pim-3 protects against cardiomyocyte apoptosis in anoxia/reperfusion injury via p38-mediated signal pathway. Int J Biochem Cell Biol 2009; 41: 2315-22.
21. Eichmann A, Yuan L, Bréant C et al. Developmental expression of Pim kinases suggests functions also outside of the hematopoietic system. Oncogene 2000; 19: 1215-24.
22. Deneen B, Welford SM, Ho T et al. PIM3 proto-oncogene kinase is a common transcription target of divergent EWS/ETS oncoproteins. Mol Cell Biol 2003; 23: 3897-908.
23. Yang XY, Ren CP, Wang L et al. Identification of differentially expressed genes in metastatic and non-metastatic nasopharyngeal carcinoma cells by suppression subtractive hybridization. Cell Oncol 2005; 27: 215-23.
24. Li YY, Popivanova BK, Nagai Y et al. Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates Bad to block Bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 2006; 66: 6741-7.
25. Popivanova BK, Li YY, Zheng H et al. Proto-oncogene, Pim-3 with serine/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent Bad-mediated apoptosis. Cancer Sci 2007; 98: 321-8.
26. Zheng HC, Tsuneyama K, Takahashi H et al. Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol 2008; 134: 481-8.
27. Arvand A, Denny CT. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 2001; 20: 5747-54.
28. Li YY, Wu Y, Tsuneyama K et al. Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells. Cancer Sci 2009; 100: 396-404.
29. Aksoy I, Sakabedoyan C, Bourillot PY et al. Self-renewal of murine embryonic stem cells is supported by the serine/threonine kinases Pim-1 and Pim-2. Stem Cells 2007; 25: 2996-3004.
30. 2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 2004; 64: 7439-46.
31. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005; 41: 2438-48.
32. Sharrocks AD. The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2001; 2: 827-37.
33. Losman JA, Chen XP, Vuong BQ et al. Protein phosphatase 2A regulates the stability of Pim protein kinases. J Biol Chem 2003; 278: 4800-5.
34. L and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-91.
35. L. Cell 1996; 87: 619-28.
36. 112 gatekeeper site. FEBS Lett 2004; 571: 43-9.
37. Yan B, Zemskova M, Holder S et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem 2003; 46: 45358-67.
38. Wu Y, Wang YY, Nakamoto Y et al. Accelerated hepatocellular carcinoma development in mice expressing the Pim-3 transgene selectively in the liver. Oncogene 2010; 29: 2228-37.
39. Mochizuki T, Kitanaka C, Noguchi K et al. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. J Biol Chem 1999; 274: 18659-66.
40. Bachmann M, Hennemann H, Xing PX et al. The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activitiy of Cdc25c-associated kinase 1 (C-TAK1). J Biol Chem 2004; 279: 48319-28.
41. cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002; 1593: 45-55.
42. Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 2007; 5: 909-22.
43. Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008; 68: 5076-85.
44. Mikkers H, Nawijin M, Allen J et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004; 24: 6104-15.
45. Beharry Z, Mahajan S, Zemskova M et al. The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci USA 2011; 108: 528-33.
46. Mikkers H, Allen J, Knipscheer P et al. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet 2002; 32: 153-9.
47. Zippo A, De Robertis A, Serafini R et al. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol 2007; 9: 932-44.
48. Zhang Y, Wang Z, Li X et al. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene 2008; 27: 4809-19.
49. Liu LM, Zhang JX, Wang JP et al. Pim-3 protects against hepatic failure in d-galactosamine (d-GalN)-sensitized rats. Eur J Clin Invest 2010; 40: 127-38.
50. Vlacich G, Nawijin MC, Webb GC et al. Pim-3 negatively regulates glucose-stimulated insulin secretion. Islets 2010; 2: 308-17.
51. Brault L, Gesser C, Bracher F et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologica malignancies. Haematologica 2010; 95: 1004-15.
52. Hu XF, Li J, Vandervalk S et al. PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 2009; 119: 362-75.
53. Kip1 peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase. J Biol Chem 2011; 286: 2681-8.
54. Holder S, Zemskova M, Zhang C et al. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol Cancer Ther 2007; 6: 163-72.
55. Pogacic V, Bullock AN, Fedorov O et al. Structural analysis identifies imidazole[1, 2-b]pyridazines as PIM kinase inhibitor with in vitro antileukemic activity. Cancer Res 2007; 67: 6916-24.
56. Chen LS, Redkar S, Bearss D et al. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2009; 114: 4150-7.
57. Xia Z, Knaak C, Ma J et al. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 2009; 52: 74-86.
58. Lin YW, Beharry ZM, Hill EG et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010; 115: 824-33.
59. Akué-Gédu R, Rossignol E, Azzaro S et al. Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors. J Med Chem 2009; 52: 6369-81.
60. Li YY, Wang YY, Taniguchi T et al. Identification of stemonamide synthetic intermediates as a novel potent anticancer drug with an apoptosis-inducing ability. Int J Cancer 2010; 127: 474-84.